AI-generated research brief — verify at source
Adding Qianlieshutong Capsules to Tamsulosin Significantly Improves CP/CPPS Symptoms Over 8 Weeks
In a randomized, double-blind trial of 240 men with chronic prostatitis/chronic pelvic pain syndrome, combining Qianlieshutong Capsules with tamsulosin produced a meaningfully greater reduction in total symptom scores than tamsulosin alone at eight weeks (14.30 vs. 10.60 points on the NIH-CPSI; mean difference 3.70, 95% CI: 2.36–5.04; P < 0.0001). The result was consistent across all symptom domains—pain, urinary symptoms, and quality of life—and the safety profiles of the two regimens were essentially indistinguishable.
What Was Studied
The trial examined whether adding Qianlieshutong Capsules (QLSTCs), a standardized traditional Chinese medicine formulation, to the alpha-blocker tamsulosin could produce superior symptom control compared with tamsulosin plus placebo in men diagnosed with NIH category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The primary measure of efficacy was the change in the total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score from enrollment to the end of the 8-week treatment period.
How It Was Studied
This was a post-marketing, multicenter, randomized, double-blind, single-dummy, parallel-group clinical trial enrolling 240 male patients between 18 and 50 years of age with a confirmed diagnosis of CP/CPPS. Participants were allocated 1:1 to either active combination therapy—QLSTCs (0.4 g per capsule, three capsules, three times daily) plus tamsulosin (0.2 mg nightly)—or a matching placebo plus tamsulosin on the same dosing schedule. Both arms were treated for eight weeks. Secondary outcomes captured symptom changes at week 4, domain-level scores for pain, urinary function, and quality of life, as well as overall treatment response and marked improvement rates. Safety monitoring encompassed adverse event reporting, laboratory investigations, vital signs, and electrocardiography.
What Was Observed
- Primary symptom outcome: At week 8, patients receiving combination therapy showed a substantially larger decline in total NIH-CPSI score than those on tamsulosin alone (14.30 ± 0.53 vs. 10.60 ± 0.54 points), representing a mean between-group difference of 3.70 points (95% CI: 2.36–5.04; P < 0.0001). This difference is statistically robust and the confidence interval excludes any possibility of a trivial or null effect.
- Treatment response and marked improvement: Both the overall effective response rate and the rate of marked clinical improvement were significantly higher in the combination arm than in the tamsulosin-plus-placebo arm, indicating that more patients crossed clinically meaningful thresholds of symptom relief when QLSTCs were added.
- Domain-specific improvements: Significant gains in favor of combination therapy were observed across all three NIH-CPSI domains—pain, urinary symptoms, and quality of life—at week 8, suggesting that the benefit of QLSTCs is broad rather than confined to a single symptom cluster.
- Safety profile: Adverse event rates were low and essentially equivalent between groups (10.00% combination vs. 9.24% tamsulosin-only), and no serious adverse events were reported in either arm, indicating that adding QLSTCs did not meaningfully increase the safety burden.
Why This Matters
CP/CPPS is characterized in this trial as a persistently difficult condition for which no universally accepted treatment exists, and for which commonly used agents such as alpha-blockers and antibiotics show inconsistent results. Demonstrating that a standardized herbal adjunct can produce incremental and statistically robust symptom relief on top of an established pharmacological backbone addresses a recognized therapeutic gap. The trial also provides structured clinical evidence for a multimodal treatment approach that integrates traditional medicine with conventional urological pharmacotherapy.
How to Read This Result
Although the trial was well-designed and the primary result is statistically strong, the 8-week follow-up duration, restriction to men aged 18–50, and the single-dummy blinding structure are methodological features that warrant consideration before drawing broad conclusions about long-term efficacy and generalizability.
Limitations
The abstract does not explicitly report study limitations.